New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
- PMID: 27797968
- DOI: 10.1158/1078-0432.CCR-16-0184
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
Abstract
Multiple myeloma is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Although new therapeutic options introduced in recent years have resulted in improved survival outcomes, multiple myeloma remains incurable for a large number of patients, and new treatment options are urgently needed. Over the last 5 years, there has been a renewed interest in the clinical potential of immunotherapy for the treatment of multiple myeloma. Clinical progression of myeloma is known to be associated with progressive immune dysregulation and loss of immune surveillance that contribute to disease progression in association with progressive genetic complexity, rendering signaling-based treatments less effective. A variety of strategies to reverse the multiple myeloma-induced immunosuppression has been developed either in the form of immunomodulatory drugs, checkpoint inhibitors, mAbs, engineered T cells, and vaccines. They have shown encouraging results in patients with relapsed refractory multiple myeloma and hold great promise in further improving patient outcomes in multiple myeloma. This review will summarize the major approaches in multiple myeloma immunotherapies and discuss the mechanisms of action and clinical activity of these strategies. Clin Cancer Res; 22(24); 5959-65. ©2016 AACR.
©2016 American Association for Cancer Research.
Similar articles
-
Immune Therapies in Multiple Myeloma.Clin Cancer Res. 2016 Nov 15;22(22):5453-5460. doi: 10.1158/1078-0432.CCR-16-0868. Clin Cancer Res. 2016. PMID: 28151713 Review.
-
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6. Pharmacotherapy. 2017. PMID: 27870103 Review.
-
Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834. Curr Cancer Drug Targets. 2017. PMID: 28201977 Review.
-
Immunopathogenesis and immunotherapy of multiple myeloma.Int J Hematol. 2018 Mar;107(3):278-285. doi: 10.1007/s12185-018-2405-7. Epub 2018 Jan 24. Int J Hematol. 2018. PMID: 29368256 Review.
-
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Immunotherapy. 2016;8(3):367-84. doi: 10.2217/imt.15.118. Epub 2016 Feb 17. Immunotherapy. 2016. PMID: 26888183 Review.
Cited by
-
Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.Cell Death Dis. 2021 Apr 14;12(4):396. doi: 10.1038/s41419-021-03685-w. Cell Death Dis. 2021. PMID: 33854043 Free PMC article.
-
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.Blood Cancer J. 2020 Oct 23;10(10):106. doi: 10.1038/s41408-020-00369-0. Blood Cancer J. 2020. PMID: 33097687 Free PMC article. Clinical Trial.
-
Mycobacterium bovis Wild-Type BCG or Recombinant BCG Secreting Murine IL-18 (rBCG/IL-18) Strains in Driving Immune Responses in Immunocompetent or Immunosuppressed Mice.Vaccines (Basel). 2022 Apr 14;10(4):615. doi: 10.3390/vaccines10040615. Vaccines (Basel). 2022. PMID: 35455364 Free PMC article.
-
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.Clin Cancer Res. 2020 Apr 1;26(7):1541-1554. doi: 10.1158/1078-0432.CCR-19-2111. Epub 2019 Oct 31. Clin Cancer Res. 2020. PMID: 31672768 Free PMC article. Review.
-
Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance.Front Oncol. 2022 Aug 5;12:894279. doi: 10.3389/fonc.2022.894279. eCollection 2022. Front Oncol. 2022. PMID: 35992875 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical